Aptevo Total Assets from 2010 to 2024
| APVO Stock | USD 10.01 0.81 8.80% |
Total Assets | First Reported 2014-12-31 | Previous Quarter 14.9 M | Current Value 15.1 M | Quarterly Volatility 36.3 M |
Check Aptevo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aptevo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 538.6 K, Interest Expense of 43.1 M or Selling General Administrative of 19.2 M, as well as many indicators such as Price To Sales Ratio of 154, Dividend Yield of 0.0 or PTB Ratio of 6.37. Aptevo financial statements analysis is a perfect complement when working with Aptevo Therapeutics Valuation or Volatility modules.
Aptevo | Total Assets |
Latest Aptevo Therapeutics' Total Assets Growth Pattern
Below is the plot of the Total Assets of Aptevo Therapeutics over the last few years. Total assets refers to the total amount of Aptevo Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aptevo Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Aptevo Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aptevo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 24.84 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Aptevo Total Assets Regression Statistics
| Arithmetic Mean | 82,325,527 | |
| Geometric Mean | 71,542,227 | |
| Coefficient Of Variation | 46.93 | |
| Mean Deviation | 35,009,572 | |
| Median | 91,858,000 | |
| Standard Deviation | 38,638,671 | |
| Sample Variance | 1492.9T | |
| Range | 96.4M | |
| R-Value | (0.94) | |
| Mean Square Error | 193T | |
| R-Squared | 0.88 | |
| Slope | (8,104,870) | |
| Total Sum of Squares | 20901.3T |
Aptevo Total Assets History
Other Fundumenentals of Aptevo Therapeutics
Aptevo Therapeutics Total Assets component correlations
Click cells to compare fundamentals
About Aptevo Therapeutics Financial Statements
Aptevo Therapeutics investors utilize fundamental indicators, such as Total Assets, to predict how Aptevo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 24.8 M | 23.6 M | |
| Intangibles To Total Assets | 0.10 | 0.09 |
Pair Trading with Aptevo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Aptevo Stock
| 0.53 | IMAB | I Mab | PairCorr |
| 0.44 | GNFT | Genfit | PairCorr |
| 0.43 | FLGC | Flora Growth Corp | PairCorr |
| 0.34 | LLY | Eli Lilly | PairCorr |
| 0.32 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Aptevo Therapeutics Correlation against competitors. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (415.99) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (2.51) |
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.